TIKOMED Successfully Closed Fundraising of 8 Million Euros

TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB-program and the IBsolvMIR® program.

TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILBprogram) and an infusion product for improving outcomes in cell therapies (IBsolvMIR® program).

“I’m delighted that we have successfully completed our latest fundraising, which demonstrates both the level of interest and trust in our clinical program from investors,” said Anders Kristensson, CEO of TIKOMED.